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ABSTRACT

We have reacted [Pt(Me4en)(D2O)2]2+ [Me4En=N,N,N’N’tetramethylethylenediamine] with Selenomethionine (SeMet), Methionine (Met), and
Methylselenocysteine (MeSeCys). When MeSeCys was reacted with
[Pt(Me4en)(D2O)2]2+, we observed both stereoisomers of Se,N chelates, as well as
[Pt(Me4en)(MeSeCys)Cl]+ from 1H NMR Spectroscopy; the latter formed due to the
presence of Cl- in the solution. Both isomers of the chelate seemed to form
proportionally to one another, not favoring a specific stereoisomer. Eventually the
[Pt(Me4en)(MeSeCys)Cl]+ products became Se,N chelates. We incubated SeMet with
NaCl for 30 minutes and then mixed with [Pt(Me4en)(D2O)2]2+; we saw equal amounts of
the [Pt(Me4en)(SeMet)Cl]+ isomers along with a specific stereoisomer of the Se,N chelate
forming first (R chirality), then approximately two hours later the (S) chirality formed.
Previously, Met and [Pt(Me4En(D2O)2]2+ have been studied by prior students and there
were no chiralities favored in the reaction. There were S,N chelates formed, but no
specific isomer favored over another. We obtained equal amounts of SeMet, Met and
[Pt(Me4en)(D2O)2]2+ and mixed the solutions together to see which amino acid would
platinate first, either SeMet or Met. The NMR spectra we observed showed that SeMet
attached first to [Pt(Me4en)(D2O)2]2+, with the (R) chelate forming first, then the (S)
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chelate. Met was slow to react, and we saw both chelates form at approximately equal
rates.

Keywords: Cisplatin, Selenomethionine, Selenocysteine, Bulky Platinum (ll) Compounds
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CHAPTER 1
INTRODUCTION
Cancer affects all races, ethnicities, genders and all locations of the world. There are
many types of cancers, some are more predominant in particular genders or races than
any others, some are slow growing while some spread very rapidly. According to the
National Cancer Institute of the Surveillance Epidemiology and End Results Statistics
Fact Sheet it is estimated that 11,957,599 men and women in the United States have had a
history of cancer by January 1, 2008.1 There are a few different options to try to treat and
cure the cancer, but there is still ongoing research to come up with more effective yet less
toxic treatments. One popular area of anticancer medication research involves the use of
platinum (II) compounds. Currently there are a few platinum anticancer medications
FDA approved for the treatment of cancers; cisplatin, carboplatin, and oxaliplatin.
Unfortunately, like many medications, side effects, resistance and toxicity become a
problem with these medications.
Figure 1:

H3N
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Figure 1 contains the structure of Cisplatin
(cis-diamminedichloroplatinum (II)).

NH3
Cl
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Cisplatin (cis-diamminedichloroplatinum (II)) was the first platinum anticancer
medication approved for the treatment of cancer by the FDA in 1978.2 The anticancer
activity was discovered by accident in the 1960’s by Barnett Rosenberg when he was
trying to monitor cell growth and division of the bacteria E. coli.2 The cell division was
inhibited while the cell growth was not bothered.2 This was later tested in sarcomas in
rats and it was found that the platinum (II) complex was very effective in reducing the
mass of the tumors.2 This finding led to other conformational testing in various tumor
cell lines and eventually led to the FDA approval of the medication for testicular and
ovarian cancers.2
The anticancer activity comes from the platinum drug binding to DNA at the N7
position of the guanine residue on the double helix, forming a crosslink. The formed
crosslink forces the double helix to bend in a distorted manner, which leads to apoptosis.
In addition to monoadducts, there are three different types of possible crosslinks that can
be formed giving rise to the anticancer activity: intrastrand crosslink, interstrand crosslink
and a DNA-protein crosslink.3 Typically a monoadduct is initially formed, but then the
complex goes on to form one of the other three crosslinks.3 High mobility group proteins
are also thought contribute to the anticancer activity.3 These proteins bind to the
platinum-DNA crosslink not allowing the cell to participate in repair mechanisms.3
A theory in chemistry called the Hard Soft Acid Base Theory; also known as the
donor-acceptor theory, helps explain why the platinum (II) complexes react with
particular amino acids and molecules. The theory was developed in the 1960’s by Ralph
Pearson.4 The idea helps explain many reactions in chemistry; a base is defined as an
electron-donor and an acid is defined as an electron-acceptor.4 A covalent bond joins the
2

two together and forms an adduct, complex or a coordination complex.4 When a
particular acid can accommodate one base (ligand) it is often referred to as a monodentate
ligand. Where as if there is more than one donatable nonbonding electron pairs it is often
referred to as either polydentate, bi-, tri-, tetra-, hexa- dentate, or chelating ligand.4 The
HSAB Theory helps in forming an idea as to what adduct will form after a reaction
because of classifying atoms as either hard/soft acids or bases. Typically hard acids are
atoms that have a relatively high charge ( ≥3+ ), small size and low electronegativity (.71.6).4 Particularly atoms located in the s and f blocks, and higher charged ions on the left
of the d block have low electronegativity.4 Hard bases usually have a high
electronegativity and are small in size. There are only 2 atoms within the
electronegativity range of 3.4-4, oxygen and fluorine.4 So, hard bases are typically ones
with either oxygen or fluorine as the donor atom. Soft acids are typically classified as
large size (1+, 2+), low charge and intermediate to high electronegativity (1.9-2.5).4
Specific examples include Hg2+, Cu+, and Ag+.4 Soft bases include those that have
intermediate to high electronegativity (2.1-3.0) and are large in size leading to
polarizability.4 Particular examples of soft bases include S2-, Se-, I-, and Br-.4
Platinum is considered a “soft acid” under the Hard/Soft Acid/Base Theory,
which means the platinum is more likely to react with “soft bases.” The atoms become
“softer” going down the columns, thus, sulfur is softer than oxygen and selenium is softer
then sulfur. These particular atoms are important because two amino acids contain a
sulfur atom, methionine and cysteine, as well as a nitrogen and oxygen atom. Selenium
is of importance because two other amino acids contain a selenium atom,
selenomethionine and selenocysteine. Selenomethionine is produced unintentionally in
3

the body while selenocysteine is made deliberately; however, it is still unknown the
purpose and function of selenomethionine. Selenocysteine, however, is currently being
called the 21st amino acid, and is known for its antioxidant properties. Since selenium is
softer then sulfur, it would be predicted that the selenium containing amino acids would
be kinetically favored in a platinum (II) complex rather than the sulfur containing amino
acids. There are proteins in the body that contain either one or more of these selenium
containing amino acids, which would also be thought that the platinum compound could
react with these proteins before it even reaches the DNA5. Typically it is thought that the
major mechanism of cell death is the binding of the platinum complex to DNA, it is also
possible that part of the mechanism could be contributed by the protein reacting with the
platinum compound as well5.
Figure 2:
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Figure 2 shows the selenomethionine
and methionine molecules.

Once cisplatin enters the blood stream it remains with its initial ligands as shown
in figure 1. The Cl- concentration is so high in the blood stream that the chlorides remain
attached to the platinum, leaving the compound at a neutral charge.5 Since it’s now
neutrally charged, the complex can enter the cytosol of the cell via the cell membrane.
Once this occurs, the chloride ligands are displaced by water molecules, now leaving the
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complex positively charged giving it the option to react with the DNA or proteins.5 If
cisplatin reacts with DNA it either leads to cell repair or cell death, while if it reacts with
proteins this can trigger toxicity and/or resistance.5
As with any drug in the medical field there are many side effects with the use of
cisplatin, including but not limited to, nephrotoxicity, hematological toxicity, ototoxicity,
neuropathy and seizures. Also, as with many chemotherapy agents, all cells in the body
are affected by the antitumor drug. Cisplatin affects the cancerous cell as well as other
normal, healthy cells in the body. With all of these many and harsh side effects on the
body, researchers are trying to develop a better, less toxic anticancer medication. It is
thought that toxicity is created by competitive protein binding and could possibly be
controlled with a rescue agent being given in conjunction with the platinum therapy.6 A
rescue agent is considered to be a sulfur-containing ligand, that can improve side effects
without affecting the antitumor activity, by either preventing or reversing the Pt-S bond
in proteins.6 But first, one must understand how the side effects are caused in the body,
what biomolecules are being affected. With basic coordination chemistry S-donor
ligands in proteins will rapidly produce the most stable bonds with Pt complexes. It can
also react with the lone pairs of N atom in amino acid side chains. There are a few amino
acids that contain an S-donor ligand, including cysteine and methionine, that are located
in particular proteins.
As stated earlier, selenium is “softer” than sulfur according to the hard-soft acidbase (HSAB) theory. Since it’s already known that Pt has a high affinity for sulfur
atoms6, it could potentially also have a high affinity for selenium-containing amino acids,
selenomethionine and selenocysteine. When Pt binds to DNA, it typically always reacts
5

with 2 adjacent guanines (specifically the N(7) atom because its more nucloephilic) more
predominantly than with anything else. Because of the square planar geometry of
cisplatin, when it bonds to guanine, the Pt-G bond rotates fast and spins freely. To slow
the rotation of the bond, bulk was added to the cisplatin molecule creating a new
platinum complex [Pt(Me4en)(D2O)2]2+ (Me4en=tetramethylethylene diamine). When
the [Pt(Me4en)(D2O)2]2+ is reacted with guanine, it slows down the rotation spin so that
one can characterize the products.3 Adding the bulk to the platinum compound has
delivered many results when reacted with guanine, as well as amino acids. For example,
when [Pt(Me4en)(D2O)2]2+ is reacted with excess methionines, a bis-product is formed.5
When reacting selenomethionine with the same platinum complex, the results are not the
same. So, with this it is important to study how these platinum compounds with bulky
ligands react with these amino acids. Using bulky platinum compounds with amino acids
has given insight to the kinetics and thermodynamics of the reaction.
Figure 3
a)

b)

N H2
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Figure 3 shows the structure of a) [Pt(Me4en)(D2O)2]2+
N,N,N’,N’,-tetramethylethylenediamine platinum (ll) diaqua,
and b) [Pt(en)(D2O)2]2+ ethylenediamine platinum (ll) diaqua

6

OD2

CHAPTER 2

MATERIALS AND METHODS

Synthesis of Pt compounds: All platinum compounds used were synthesized by
other students in the Dr. Williams’ lab based on methods of Williams et al.6 For
[Pt(Me4en)(D2O)2]2+, all solutions were made as a 10 mM solution, using 4.4 mg of the
platinum compound and 1 mL of deuterium oxide. [Pt(en)(D2O)2] solutions were made
using 4.1 mg of the platinum compound in 1mL of deuterium oxide.
Preparation of solutions: All amino acid containing compounds in solutions
were all made to be around 5 to 10 mM, and around a pH of 4 to 5. For the reaction
involving SeMeCys and Pt(Me4en), the platinum compound was made as a

10 mM

solution using 4.4 mg of platinum compound in 1 mL of deuterium oxide. SeMeCys was
made as 1.4 mg of amino acid in 1 microliter of deuterium oxide giving a 10 mM
solution. The final solution was made to be 300 microliters of each mixed together to
give a final concentration of 5 mM.
For the reaction involving selenomethionine, sodium chloride and
[Pt(Me4en)(D2O)2]2+, 0.3 mg of sodium chloride was mixed with the platinum compound
and allowed to mix for 30 minutes. Selenomethionine was made using 4.1 mg of
selenomethionine in 1 mL of deuterium oxide. Then using theselenomethionine at pH 4,
it is mixed with the sodium chloride and platinum solution; 300 microliters were used of
each solution to mix. Also, we wanted to mix the same reactants together, but add the
7

sodium chloride to the solution at a different time. For this reaction, 500 microliters of
the selenomethionine solution and added 0.3mg of sodium chloride and allowed to mix
for 30 minutes and achieve a final pH of 7.66. Then, adding 300 microliters of this
SeMet-NaCl solution, to 300 microliters of the [Pt(Me4en)(D2O)2]2+ solution.
The solutions of SeCys with Pt(en) were made at different ratios, for the 2:1 ratio
solutions they were made via the following reaction. 1 mg of SeCys was first mixed in
1mL of deuterium oxide and then the pH was raised to 7, then 2.5 mg of the platinum
compound was added. The pH was then checked and raised back to a pH of around 7.
The second 2:1 solution the pH was not raised back up to 7 after adding the platinum
compound, it was left around a pH of 3. For the 1:1 solutions, 1 mg of SeCys was mixed
with 1 mL of deuterium oxide and then the pH of was raised to 7 to allow for solubility.
Then 1.2mg of platinum compound was raised to the SeCys solution made and the pH
was then raised back up to 7. The pH of the second 1:1 solution was not adjusted back to
7, it was left at around a pH of 3.
The solutions containing SeMeCys and Pt(en) were also made at different pH’s.
The first solution was made by 1.1 mg SeMeCys in 1 mL of deuterium oxide and then 2.5
mg of Pt(en) were added and left at pH 3. The second solution was made using same
amount SeMeCys and same amount of the platinum compound except the pH was then
raised back up to 7.

8

CHAPTER 3

RESULTS
Reaction of MeSeCys and [Pt(Me4en)(D2O)2] 2+ . The addition of
methyl-selenocysteine (MeSeCys) to [Pt(Me4en)(D2O)2]2+ led to a mono adduct at the Se
atom; figure 5 shows the mono adduct. The MeSeCys used in the experiment contains
the chloride ion in the commercial sample. When Se binds to Pt this is what leads to the
two different isomers seen in the NMR spectrum. Initially, both isomers of the mono
adduct are seen, Pt(Me4en)(MeSeCys-Se),(D2O) 2+. With the chloride in the mixture the
mono adduct formed as well, [Pt(Me4en)(Cl)(MeSeCys)] +, with a characteristic singlet at
2.45 ppm and 2.31 ppm using 1H NMR. Eventually, the chloride ions dissociate from the
complex allowing both isomers of the Se,N chelate to form, Pt(Me4en)(MeSeCys-Se,N)+,
at 2.56 ppm and 2.49 ppm. Over time the chloride adducts were forming proportionally
to the MeSeCys chelates, and that both isomers of the Se,N chelate were forming
relatively proportional to one another. With both 1H NMR signals from the Se,N chelate
forming at about the same rate, this is associated with no particular stereoisomer being
preferred during the reaction. Eventually, both of the chloride mono adduct signals
slowly diminish giving rise to more Se,N chelates forming and allowing free chloride to
form.

9

Figure 4:

Figure 4 shows the 1H NMR
spectrum for our reaction
MeSeCys and Pt(Me4en) the
initial reaction. Here the
MeSeCys chelates are noted.

MeSeCys chelates

3.0 ppm

2.0 ppm

Figure 5:
MeSeCys Chelates

Chloride adducts

2.58

2.49

2.40

In this NMR spectra both chelates are
forming at around equal rates, while the
chloride adduct signal still growing.

2.58

2.49

10

2.40

Figure 5: Overall in these spectrum from the kinetics run, the MeSeCys chelates
that have formed, no isomer is preferred when forming. Also seen here the
chloride adducts form, but eventually convert to all MeSeCys chelates.

2.58

2.40

2.49

Figure 6:
MeSeCys chelates

2.6

2.40
Figure 6: Here, approximately 24 hours later, the chloride adducts
have converted to all MeSeCys chelates in solution.

Reaction of [Pt(Me4en)(D2O)2 ] 2+, SeMet and NaCl. When the last experiment with
MeSeCys allowed both isomers of the Se,N chelate to be seen, it was decided to add NaCl
to Pt(Me4en)(D2O)22+. After approximately 30 minutes, the chloride mono adduct is
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forming, [Pt(Me4en)(Cl)(D2O)]+, associated with 1H NMR singlets at 2.84 ppm and 2.85
ppm.6 When adding the [Pt(Me4en)(Cl)(D2O)]+ to SeMet, two peaks are seen at 2.38 and
2.39 ppm that grew at approximately equal rates and formed [Pt(Me4en)(SeMet-Se)Cl]+.6
After approximately 5 days the chloride ligand dissociate from the complex and allow the
Se,N chelate to form singlets at approximately 2.58 ppm and 2.48 ppm by 1H NMR
[Pt(Me4en)(SeMet-Se,N)]+.6
The same experiment was completed with equal molar concentrations but
changed what the incubated NaCl was mixed with. First, NaCl was reacted with SeMet
for 30 minutes and then added [Pt(Me4en)(D2O)2]2+. Immediately the form monochloride adducts with singlets at 2.38 and 2.39 ppm, [Pt(Me4en)(SeMet-Se)Cl]+, and the
same Se,N chelates at 2.58 and 2.48 ppm. With both isomers of the chelate,
[Pt(Me4en)(SeMet-Se,N)]+ forming singlets at 2.58 and 2.48 ppm on the 1H NMR
spectrum. First, the R isomer shows up immediately and a little of the S isomer is a little
slower reacting. After approximately two hours both isomers have formed equal
amounts. Here it’s discovered that since there are the two isomers showing with a
preference for one over the other, obviously one is easier to form than the other. With the
methyl group of the SeMet giving direction towards the bulky Me4en ligand in the (S)
position, it is less likely to form due to the bulkiness of the ligand and because of the
sterics that are created when the Se,N chelate forms. However, when the methyl group is
directed outward from the Me4en ligand, the chelate is easier to form, thus giving a larger
singlet signal on the NMR spectrum.
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Figure 7:
SeMet Chelate (R) Isomer

Figure 7: Here we see at the begininning of the
reaction the R isomer is already predominiately formed,
while the S isomer has barely even formed at all. We
can also see here the chloride adducts have also formed
again, showing both isomers of the monoadducts that
formed.
Chloride Adducts

SeMet Chelate (S) Isomer

2.40

2.50

SeMet Chelate (R) Isomer

SeMet Chelate (S) Isomer

2.50

Chloride Adducts

2.40

Reaction of [Pt(en)(NO3)2 ]2+ and SeCys: In the following reactions, SeCys was added
to D2O and then the pH was raised to 7 to allow SeCys to fully dissolve in solution7.
After pH was adjusted and SeCys was in solution, [Pt(en)(NO3)2 ]2+ was added. When
the platinum complex was added to the SeCys the pH would immediately drop to
approximately 3. Then either the solution was left at pH 3 or brought back up to around
pH 7. There were four different solutions made, two pH 7 solutions and two pH 3
solutions, all with different amounts of [Pt(en)(NO3)2]2+.
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The first solution made was a 2:1 ratio, meaning there were two platinum
complexes for every one selenocysteine complex in solution, and the pH was brought
back up to 7. This would allow for one platinum atom for every one selenium atom in
solution. The second solution made was also brought back up to pH 7, but this was made
as a 1:1 ratio, meaning there was one platinum complex for every one selenocystine
complex. This gives one platinum atom per two selenium atoms in solution. The initial
color of both solutions was yellow, approximately four days later the solution had turned
colorless with black precipitate in it. The pH of the 2:1 solution dropped to 4.40 after
four days, while the 1:1 solution dropped to pH 5.30 after four days. The 1H NMR
spectrum showed that the en ligand stayed on both platinum compounds during the
reaction because there were no peaks at or around 3.33 ppm, which is typically where the
singlet for the en ligand would be.
Both of the pH 3 solutions were made the same way, one was a 2:1 ratio at pH 3
and the other was a 1:1 ratio at pH 3. Initially the solutions were colorless with no
precipitate, while four days later both solutions had turned yellow with black precipitate
in it. The color changes led to checking the pH of both solutions and in fact the pH had
dropped. For the solution that was a 2:1 ratio the solution dropped to 1.90, while the 1:1
ratio solution was 2.90. Taking a look at both solutions after another four more days and
the solution had turned a darker yellow-brown color with the black precipitate still in it.
The pH of both solutions was checked again, while the 2:1 ratio solution had remained
the same, the 1:1 ratio had actually increased to 3.50. After running both solutions in the
NMR, it was noted that the en ligand had come off of the platinum compound by the
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singlet at 3.338. Typically the ligand dissociation requires two Se ligands to be
coordinated to the complex.
Both solutions that were initially at pH 7 were dropped to pH 3 to see if the en
ligand would dissociate from the platinum complex. Both ratios of the platinum complex
were left the same, but adjusted the pH back to 3, and both solutions remained colorless
even after the pH adjustment was made. Initially with the NMR spectrum there were no
new peaks noted, however, a few peaks on the spectrum continuously decreased in size
when it reached 48 hours after making the pH adjustment. There is a singlet at 2.33 ppm
that occurs at pH 7 with both ratios of solutions; however, after dropping the pH back
down to 3, the singlet eventually completely diminishes. Continuously monitoring this
reaction for about a week, the en ligand never comes off of the platinum complex.
Reaction of SeMeCys and [Pt(en)(NO3)2]2+: The last experiment gave the idea to try
SeMeCys and the same platinum complex used above in the next reactions. For one
solution the pH was left at 3 after mixing in the platinum complex, and then raised the pH
of the other solution back to 7 after mixing in the platinum complex.
The first solution was made at a pH of 3, and an overnight kinetic reaction was
ran for 12 hours on the 1H NMR. Based upon the singlet at 3.33 ppm, this shows that the
en ligand comes off of the main platinum compound. The peak is seen pretty quickly in
the reaction, actually almost immediately.
The second solution was made and then raised back up to a pH of 7 and a proton
kinetics run was completed. With the solution being at a higher pH than the previous
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solution, the en ligand never comes off. Comparing data from the initial run and a few
weeks later, the 3.33 ppm peak never shows up.
With both solutions, a significant amount of unreacted SeMeCys and Pt(en) was
seen during the course of both reactions. These reactions also help reiterate that the en
ligand comes off at a low pH, and doesn’t at a higher pH.
Figure 8:

Figure 8: This is the initial mixing of
the pH 3 sample of MeSeCys and
Pt(en) for the NMR

2.33 ppm

3.5 ppm

Figure 9:

Figure 9: This is the same reaction at
the same pH only 15 hours later. The
unreacted platinum complex and
MeSeCys is still seen here.

3.5 ppm

2.33 ppm

16

CHAPTER 4

DISCUSSION
Part of the purpose of these experiments was to see the effects that bulky platinum
(II) compounds have when reacted with selenium-containing amino acids, in particular
selenomethionine and selenocysteine. Due to being unable to actually purchase
selenocysteine, methylselenocysteine (MeSeCys) and selenocystine (SeCys) were
purchased. Initially it was wanted to start working with selenocysteine and reacting it
with the platinum compounds, methylselenocysteine was used first. After this reaction
was completed, the obtained results showed that two isomers were being formed, which
was caused from there being a chloride ion in solution from the methylselenocysteine.
This gave the idea to try sodium chloride with selenomethionine and the platinum
compound to see if any steric effects or isomers were forming. Back to the
selenocysteine idea, it was ended up that using selenocystine for the next reactions with
the Pt(en) compound. After not getting very good results, next the methylselenocysteine
with the Pt(en) compound was repeated; this also did not help come to any conclusion for
the seleocysteine project.
When the MeSeCys reacted with the Pt(Me4en) compound, the chloride adduct
and MeSeCys chelate signals had formed in the NMR spectrum. Over time the chloride
adducts begin to form relatively proportional to the MeSeCys chelates being formed.
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Eventually the chloride adducts dissociate from the platinum compound, which was
shown by the NMR spectra, leaving with only two peaks for both isomers of the chelates
being formed. This information explains that the chloride ions from the MeSeCys are
removed from the amino acid to form a monoadduct with the Pt(Me4en) complex. Also,
both isomers of the MeSeCys chelates form at relatively proportional rates. When this
showed that both isomers for the chelates were being formed, it was decided to try a
similar reaction with selenomethionine and the same platinum compound.
For the similar reaction sodium chloride was incorporated two different ways into
the solution. The Pt(Me4en) complex was mixed with sodium chloride and after
approximately 30 minutes there were peaks that were associated with the formation of
[Pt(Me4en)(D2O)Cl]+. There were two singlets formed at 2.84 ppm and 2.85 ppm that
were essentially assigned to the two methyl groups of the Me4en ligand. Then the
selenomethionine was added to the solution, this gave peaks at 2.38 and 2.39 ppm, that
corresponds to the Se-CH3 groups formed by the product [Pt(Me4en)(SeMet-Se)Cl]+.
After approximately 5 days, these monoadducts form to Se-N chelates giving
[Pt(Me4en)(SeMet-Se,N)+. It also noted that with the isomers that were formed, one was
forming at a relatively fast rate compared to the other. The R isomer was formed first and
slowly the S isomer was formed. The methyl group from the SeMet is sterically hindered
from the methyl groups of the platinum complex. When the S isomer is formed, there is
less room for the methyl group to exist, thus it wouldn’t be expected to see this isomer
form particularly fast. When the R isomer is formed, there isn’t anything sterically
hindering the methyl group, thus it is easier and faster in forming the chelate. Also, the
SeMet was mixed with sodium chloride and allowed to mix for 30 minutes, then adding
18

the platinum compound. With this experiment, the same results are seen as did with the
previous way the solution was mixed. The R isomer forms first and then slowly the S
isomer forms. However, with this mixture the monoadduct is not seen like that its
formed in the previous experiment. Finally, it was finally obtained, a great NMR
spectrum for the isomers involved in the chelate formation, eventually it was decided to
try the SeCys with a different platinum compound.
Using selenocystine with the Pt(en) complex gave very interesting results,
however, it has not been able to classify peaks and determine what type of products that
are obtained. With these experiments, a few things were noted, like color change and
precipitate being formed in solution. For example, both of the solutions that were at a
final pH of 7, were both translucent, but had a color of yellow. But with both solutions
that had final pH’s of 3 were both translucent, colorless. 2 days later a color change in
solution were seen, both solutions that were initially yellow went colorless and formed a
moderate amount of black precipitate. Both solutions that were initially colorless, had
changed to a pale yellow color and also had black precipitate in solution that had formed
2 days later.
NMR data together was put together to obtain some information to help determine
what is being formed in solution. Both concentrations of solutions at a pH of 3 showed
on NMR data that the ‘en’ ligand dissociated from the platinum complex; while at a pH
of 7, it did not. This can be concluded that the ‘en’ ligand is capable of coming off, but
only at a low pH. There were also other peaks noted in the NMR spectra that were
relatively similar to one another, but also one of the pH solutions would have a peak
somewhere that the other did not. For example, at a pH of 7, peaks at 2.8 ppm and 2.2
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ppm are seen, but it’s not seen in the pH 3 solution NMR spectrum. But at both pH’s
there are peaks at 2.5 and 2.6 ppm. At the time of writing this thesis, we have not come
up with any conclusions for what these peaks are. We have tried other experiments to try
to see if we can figure it out, we have also done liquid/chromatography mass
spectrometry, but have also not come up with any solid answers yet.
This experiment was completed using one solution at a pH of 3 and the other at 7,
both solutions was also mixed as one platinum molecule for every one selenium
molecule. Here, the pH 3 solution shows the ‘en’ ligand comes off again, but does not at
pH 7. Inconclusive results were obtained for this experiment as well. We have not
completed any mass spectrometry at the time of the thesis being written.
It is important however, that with the latter of the experiments we make a note
that the ‘en’ ligand only comes off here with a low pH of around 3, rather than at a higher
pH of around 7. For prior experiments in this thesis, we have finally captured the isomers
being formed of the chelates for SeMet and Me4en, and the monoadducts that formed.
Prior to this experiment it was noted that the monoadducts were formed so fast, it had not
been captured, and there was no information on the stereochemistry formed from these
reactants as well. Now that we have made a few conclusions with a few bulky platinum
compounds and these two selenium containing amino acids, we will continue to further
explore other bulky platinum compounds with the amino acids. We will also further
investigate our SeCys and Pt(en) compounds and get some finite results and answers and
publish them.
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Platinum compounds have been used alone and also in conjunction with other
anti-cancer agents to fight the battle of cancer. Since platinum has a high affinity for
sulfur containing amino acids and proteins, it also has an even higher affinity for
selenium containing amino acids and proteins. These results produced in this research
have contributed to the cancer research being conducted, it also gives insight into further
research areas to explore.
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